PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

WSU researchers see link between hunter-gatherer cannabis use, fewer parasites

Study suggests unconscious use of 'medical marijuana'

2015-06-01
(Press-News.org) VANCOUVER, Wash.--Washington State University researchers have found that the more hunter-gatherers smoke cannabis, the less they are infected by intestinal worms. The link suggests that they may unconsciously be, in effect, smoking medical marijuana. Ed Hagen, a WSU Vancouver anthropologist, explored cannabis use among the Aka foragers to see if people away from the cultural and media influences of Western civilization might use plant toxins medicinally. "In the same way we have a taste for salt, we might have a taste for psychoactive plant toxins, because these things kill parasites," he said. In an earlier study, Hagen found that the heavier tobacco smokers among the Aka also had fewer helminths, parasitic intestinal worms. He cautions, however, that the studies have their limits. While nicotine has been seen killing worms in livestock, that hasn't been directly demonstrated in humans. Cannabis kills worms in a petri dish, but researchers have not shown it killing worms in animals, Hagen said. The Aka are a "pygmy" people of the Congo basin. As one of the world's last groups of hunter-gatherers, they offer anthropologists a window into a way of life accounting for some 99 percent of human history. They might also offer an alternative hypothesis to explain human drug use. The prevailing explanation is that recreational drugs "hijack the pleasure centers of the brain," making people feel good. But they also trigger mechanisms that tell us we're consuming something toxic, tasting bitter and making us feel sick. "So we thought, 'Why would so many people around the world be using plant toxins in this very 'recreational' way?" said Hagen. "If you look at non-human animals, they do the same thing, and what a lot of biologists think is they're doing it to kill parasites." The issue is significant on at least two fronts, write Hagen and his colleagues, with substance abuse and intestinal helminth infection being "two of the developing world's great health problems." Their study appears in the American Journal of Human Biology. Researchers are unsure when the Aka might have first smoked cannabis or when it arrived on the continent. It may have come with traders from the Indian subcontinent around the first century A.D., but Hagen and his colleagues say it might not have been smoked until European colonization in the 17th Century. Hagen surveyed almost all of the nearly 400 adult Aka along the Lobaye River in the Central African Republic and found roughly 70 percent of the men and 6 percent of the women used cannabis. The polling was supported by bioassays of the men that found high enough levels of THCA, a metabolic byproduct of cannabis's active ingredient, to indicate that 68 percent of them had recently smoked. Stool samples collected from the men to gauge their worm burden found some 95 percent of them were infected with helminths. But those who consumed cannabis had a significantly lower rate of infection. A year after being treated with a commercial antihelmintic, the cannabis users were reinfected with fewer worms. While the Aka deliberately consume a tea of a local plant, motunga, to fight parasitic infections, they do not think of cannabis or tobacco as medicine, Hagen said. This suggests they are unconsciously using cannabis to ward off parasites, he said.

INFORMATION:

Hagen's co-authors on the study are Casey Roulette, who did the research as part of his WSU PhD, and Pasteur Institute researchers Mirdad Kazanji and Sébastien Breurec.



ELSE PRESS RELEASES FROM THIS DATE:

Discovery could improve radiotherapy for wide range of cancers

2015-06-01
Cancer Research UK scientists have discovered how giving a class of drugs called AKT inhibitors in combination with radiotherapy might boost its effectiveness across a wide range of cancers, according to a study published in the Journal of Clinical Investigation today*. Tumours often grow so quickly that some of the cells do not have access to the body's blood supply, causing them to become oxygen-starved. This rapid growth usually sends signals to the cells to die, but in cancers with faults in a gene called p53 -- present in at least half of all cancers -- this signal ...

Article concludes no reason for laughing gas to be withdrawn from operating theaters

2015-06-01
A debate at this year's Euroanaesthesia meeting in Berlin will focus on whether laughing gas (nitrous oxide) should be banned from the operating room. The debate coincides with an article on the "Current place of nitrous oxide in clinical practice" published in the European Journal of Anaesthesiology, that concludes there is "no clinically relevant evidence for the withdrawal of nitrous oxide from the armamentarium of anaesthesia practice or procedural sedation." The article has been prepared by a special taskforce of the European Society of Anaesthesiology (ESA), which ...

American surgery patients -- more pain medication, yet more pain!

2015-06-01
New research presented at this year's Euroanaesthesia conference in Berlin shows that American patients undergoing orthopaedic surgery* receive more treatments for pain and that their experience of pain differs in some aspects to orthopaedic patients internationally. The study is by Drs Winfried Meissner and Ruth Zaslansky, University Hospital Jena, Germany, and Dr C. Richard Chapman Utah, Pain Research Center, Salt Lake City, USA. All researchers are part of the international PAIN OUT** research group. Poorly controlled pain after surgery is a major problem internationally ...

Preoperative statins reduce mortality in coronary artery bypass graft surgery

2015-06-01
Research presented at this year's Euroanaesthesia exploring the protective effect of various heart medications that patients are taking before undergoing coronary artery bypass graft (CABG) surgery concludes that statins reduce the risk of death by two thirds, or 67 percent, while no consistent effects were seen for other medications. The study is reported by Assistant Professor Dr. Robert Sanders, Anesthesiology & Critical care Trials & Interdisciplinary Outcomes Network (ACTION), Department of Anesthesiology, University of Wisconsin, Madison, WN, USA, and Drs. Puja Myles ...

Immunotherapy drug improves survival for common form of lung cancer

2015-06-01
In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months longer than those receiving chemotherapy. Squamous non-small cell lung cancer accounts for 25 to 30 percent of all lung malignancies. Results of the trial, reported in the May 31 issue of the New England Journal of Medicine and presented at the American Society for Clinical Oncology 2015 annual meeting, also showed that after a year, the nivolumab ...

Contact lens wearers note: Your eyes may get more infections because their microbiomes changed

2015-05-31
Using high-precision genetic tests to differentiate the thousands of bacteria that make up the human microbiome, researchers at NYU Langone Medical Center suggest that they have found a possible -- and potentially surprising -- root cause of the increased frequency of certain eye infections among contact lens wearers. In a study report on their work to be presented at the annual meeting of the American Society for Microbiology on May 31 in New Orleans, NYU Langone researchers say they have identified a diverse set of microorganisms in the eyes of daily contact lens wearers ...

Immunotherapy combo increases progression-free survival in advanced melanoma patients

2015-05-31
CHICAGO, IL, MAY 31, 2015 -- Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each ...

Removing more breast tissue reduces by half the need for second cancer surgery

2015-05-30
New Haven, Conn. -- Removing more tissue during a partial mastectomy could spare thousands of breast cancer patients a second surgery, according to a Yale Cancer Center study. The findings were published online May 30 in the New England Journal of Medicine and presented at the 2015 Annual Meeting of the American Society of Clinical Oncology in Chicago. Nearly 300,000 women in the United States are diagnosed with breast cancer each year; more than half undergo breast-conserving surgery with a partial mastectomy to remove the disease. However, between 20% and 40% of patients ...

Targeted drug can 'diminish the suffering' of myelofibrosis say Mayo Clinic researchers

2015-05-30
CHICAGO -- Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a Mayo Clinic researcher who co-led PERSIST-1, the worldwide phase III clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent. Investigators further found that pacritinib could be used safely in patients with myelofibrosis who ...

Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients

2015-05-30
CHICAGO -- Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), an interim analysis has closed the international HELIOS phase III clinical trial. Led by Mayo Clinic, researchers found that ibrutinib and chemotherapy (bendamustine and rituximab, known as BR) reduced the risk of death or cancer progression by almost 80 percent in patients with previously treated CLL or SLL, compared to use of BR alone. The announcement was made at ...

LAST 30 PRESS RELEASES:

Global cervical cancer vaccine roll-out shows it to be very effective in reducing cervical cancer and other HPV-related disease, but huge variations between countries in coverage

Negativity about vaccines surged on Twitter after COVID-19 jabs become available

Global measles cases almost double in a year

Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen

Personalised “cocktails” of antibiotics, probiotics and prebiotics hold great promise in treating a common form of irritable bowel syndrome, pilot study finds

Experts developing immune-enhancing therapies to target tuberculosis

Making transfusion-transmitted malaria in Europe a thing of the past

Experts developing way to harness Nobel Prize winning CRISPR technology to deal with antimicrobial resistance (AMR)

CRISPR is promising to tackle antimicrobial resistance, but remember bacteria can fight back

Ancient Maya blessed their ballcourts

Curran named Fellow of SAE, ASME

Computer scientists unveil novel attacks on cybersecurity

Florida International University graduate student selected for inaugural IDEA2 public policy fellowship

Gene linked to epilepsy, autism decoded in new study

OHSU study finds big jump in addiction treatment at community health clinics

Location, location, location

Getting dynamic information from static snapshots

Food insecurity is significant among inhabitants of the region affected by the Belo Monte dam in Brazil

The Society of Thoracic Surgeons launches new valve surgery risk calculators

Component of keto diet plus immunotherapy may reduce prostate cancer

New circuit boards can be repeatedly recycled

Blood test finds knee osteoarthritis up to eight years before it appears on x-rays

April research news from the Ecological Society of America

Antimicrobial resistance crisis: “Antibiotics are not magic bullets”

Florida dolphin found with highly pathogenic avian flu: Report

Barcodes expand range of high-resolution sensor

DOE Under Secretary for Science and Innovation visits Jefferson Lab

Research expo highlights student and faculty creativity

Imaging technique shows new details of peptide structures

MD Anderson and RUSH unveil RUSH MD Anderson Cancer Center

[Press-News.org] WSU researchers see link between hunter-gatherer cannabis use, fewer parasites
Study suggests unconscious use of 'medical marijuana'